BRPI0313155B8 - composto químico derivado ou análogo de carotenóide, composição farmacêutica, e, uso do composto - Google Patents
composto químico derivado ou análogo de carotenóide, composição farmacêutica, e, uso do compostoInfo
- Publication number
- BRPI0313155B8 BRPI0313155B8 BRPI0313155A BR0313155A BRPI0313155B8 BR PI0313155 B8 BRPI0313155 B8 BR PI0313155B8 BR PI0313155 A BRPI0313155 A BR PI0313155A BR 0313155 A BR0313155 A BR 0313155A BR PI0313155 B8 BRPI0313155 B8 BR PI0313155B8
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- analog
- administered
- analogs
- subject
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 235000021466 carotenoid Nutrition 0.000 title abstract 4
- 150000001747 carotenoids Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000007845 reactive nitrogen species Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 150000001514 astaxanthins Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
Abstract
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39919402P | 2002-07-29 | 2002-07-29 | |
US46797303P | 2003-05-05 | 2003-05-05 | |
US47283103P | 2003-05-22 | 2003-05-22 | |
US47374103P | 2003-05-28 | 2003-05-28 | |
US48530403P | 2003-07-03 | 2003-07-03 | |
PCT/US2003/023706 WO2004011423A2 (en) | 2002-07-29 | 2003-07-29 | Structural carotenoid analogs for the inhibition and amelioration of disease |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0313155A BR0313155A (pt) | 2005-07-12 |
BRPI0313155B1 BRPI0313155B1 (pt) | 2018-11-06 |
BRPI0313155B8 true BRPI0313155B8 (pt) | 2021-05-25 |
Family
ID=31192475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0313155A BRPI0313155B8 (pt) | 2002-07-29 | 2003-07-29 | composto químico derivado ou análogo de carotenóide, composição farmacêutica, e, uso do composto |
Country Status (12)
Country | Link |
---|---|
US (5) | US7145025B2 (pt) |
EP (2) | EP2392562B1 (pt) |
JP (2) | JP4601549B2 (pt) |
KR (1) | KR20050069975A (pt) |
CN (2) | CN101845009B (pt) |
AU (1) | AU2003256982A1 (pt) |
BR (1) | BRPI0313155B8 (pt) |
CA (1) | CA2495167C (pt) |
HK (2) | HK1084380A1 (pt) |
MX (1) | MXPA05001202A (pt) |
NO (1) | NO20050619L (pt) |
WO (1) | WO2004011423A2 (pt) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60229416D1 (de) | 2001-10-25 | 2008-11-27 | Univ Emory | Katheter für modifizierte Perfusion |
US20070160645A1 (en) * | 2001-10-25 | 2007-07-12 | Jakob Vinten-Johansen | PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs |
JP2005518453A (ja) * | 2002-02-25 | 2005-06-23 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 二極性トランスカロテノイド塩およびそれらの使用 |
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US7723327B2 (en) * | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
US7375133B2 (en) * | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050049248A1 (en) * | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
US20050009788A1 (en) * | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
US20050059635A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
US20050026874A1 (en) * | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
US20050059659A1 (en) * | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
US7345091B2 (en) * | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
EP2392562B1 (en) | 2002-07-29 | 2018-03-07 | Cardax Pharma, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
US20050004235A1 (en) * | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
US7320997B2 (en) * | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
US7763649B2 (en) * | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
WO2005069998A2 (en) | 2004-01-20 | 2005-08-04 | Brigham Young University Technology Transfer Office | Novel sirtuin activating compounds and methods for making the same |
US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
WO2005102356A1 (en) * | 2004-04-14 | 2005-11-03 | Hawaii Biotech, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20060111580A1 (en) * | 2004-10-01 | 2006-05-25 | Lockwood Samuel F | Methods for the synthesis of chiral dihydroxy ketone intermediates useful for the chiral synthesis of carotenoids |
JP2007238441A (ja) * | 2004-12-03 | 2007-09-20 | Fuji Chem Ind Co Ltd | アスタキサンチンを有効成分とする体脂肪減少用組成物 |
JP2008525468A (ja) * | 2004-12-22 | 2008-07-17 | エモリー・ユニバーシティ | ポストコンディショニング臓器保護作用を増強する治療補助薬 |
US20060270589A1 (en) * | 2005-02-22 | 2006-11-30 | Lockwood Samuel F | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities |
EP2540696B1 (en) * | 2005-02-24 | 2020-01-01 | Diffusion Pharmaceuticals LLC | Trans carotenoids, formulation and uses |
CA2606329A1 (en) * | 2005-03-09 | 2006-09-21 | Cardax Pharmaceuticals, Inc. | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
EP2371967B1 (en) | 2005-03-18 | 2015-06-03 | DSM IP Assets B.V. | Production of carotenoids in oleaginous yeast and fungi |
WO2006102576A1 (en) * | 2005-03-23 | 2006-09-28 | Cardax Pharmaceuticals, Inc. | Water-dispersible carotenoids, including analogs and derivatives |
CA2610502A1 (en) * | 2005-03-29 | 2006-10-05 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
JP2006016407A (ja) * | 2005-06-15 | 2006-01-19 | Yamaha Motor Co Ltd | ホスホジエステラーゼ阻害剤 |
JP2006016408A (ja) * | 2005-06-23 | 2006-01-19 | Yamaha Motor Co Ltd | 血中中性脂肪抑制剤 |
JP2007153845A (ja) * | 2005-12-07 | 2007-06-21 | Yamaha Motor Co Ltd | 脂肪蓄積抑制剤 |
US20070238793A1 (en) * | 2005-12-07 | 2007-10-11 | Lockwood Samuel F | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status |
US20070135521A1 (en) * | 2005-12-14 | 2007-06-14 | Yamaha Hatsudoki Kabushiki Kaisha | Agent for Preventing Metabolic Syndrome |
WO2007090095A2 (en) * | 2006-01-27 | 2007-08-09 | Cardax Pharmaceuticals, Inc. | Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics |
WO2007147163A2 (en) * | 2006-06-16 | 2007-12-21 | Cardax Pharmaceuticals, Inc. | Compositions comprising carotenoid analogs or derivatives and methods for synthesis |
PT2051595E (pt) * | 2006-08-08 | 2016-02-09 | Nestec Sa | Composições biodisponíveis e estáveis de isómeros de carotenoides para a pele e cabelo |
US8691555B2 (en) | 2006-09-28 | 2014-04-08 | Dsm Ip Assests B.V. | Production of carotenoids in oleaginous yeast and fungi |
ITMI20061874A1 (it) * | 2006-09-29 | 2006-12-29 | Rosario Ammirante | Composizione per il trattamento degli stati patologici neurodegenerativi del sistema nervoso centrale ed in particolare nel morbo di parkinson |
US8063101B2 (en) * | 2007-03-23 | 2011-11-22 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives for the prevention of platelet aggregation |
EP3483140A1 (en) * | 2007-04-13 | 2019-05-15 | Diffusion Pharmaceuticals LLC | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
CA2703946A1 (en) * | 2007-10-31 | 2009-05-07 | Diffusion Pharmaceuticals Llc | A new class of therapeutics that enhance small molecule diffusion |
US20090297492A1 (en) * | 2008-05-30 | 2009-12-03 | Yamaha Hatsudoki Kabushiki Kaisha | Method for Improving Cognitive Performance |
WO2010120686A2 (en) * | 2009-04-13 | 2010-10-21 | Parsons J Kellogg | Methods for the diagnosis and treatment of benign prostatic hyperplasia |
KR101875843B1 (ko) | 2009-06-22 | 2018-07-06 | 디퓨젼 파마슈티컬즈 엘엘씨 | 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도 |
JP5863656B2 (ja) * | 2009-09-11 | 2016-02-16 | ネステク ソシエテ アノニム | 動物の認知機能及び認知関連機能を向上させるための組成物及び方法 |
US8541645B2 (en) * | 2009-10-22 | 2013-09-24 | University Of Calcutta | Animal model for cigarette-smoke-induced atherosclerosis and related methods |
AU2011262361A1 (en) | 2010-06-02 | 2013-01-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
WO2012017033A1 (en) * | 2010-08-04 | 2012-02-09 | Ieo-Istituto Europeo Di Oncologia S.R.L. | Method of antigen loading for immunotherapy |
CN102389407A (zh) * | 2011-12-01 | 2012-03-28 | 滨州医学院 | 虾青素在制备治疗和预防肺纤维化的药品中的应用 |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
GB201120772D0 (en) * | 2011-12-02 | 2012-01-11 | Ip Science Ltd | Cocoa-based food products |
CN104780782A (zh) * | 2012-07-09 | 2015-07-15 | 诺格罗有限责任公司 | 使用膳食补充剂预防酒精反应 |
CN103073471B (zh) * | 2013-01-30 | 2014-11-05 | 江苏省农业科学院 | 一种叶黄素二琥珀酸酯的超声辅助合成方法 |
US9482675B1 (en) * | 2013-07-31 | 2016-11-01 | University Of Kentucky Research Foundation | Methods and systems for prognosis and diagnosis of brain damage |
JP6183746B2 (ja) * | 2013-11-13 | 2017-08-23 | 国立大学法人高知大学 | 遅延性アレルギー抑制剤 |
SG11201609405VA (en) * | 2014-05-20 | 2016-12-29 | Fuji Chem Ind Co Ltd | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof |
EP3207028B1 (en) * | 2014-10-19 | 2020-05-27 | Shenkar College of Engineering and Design | Astaxanthin based polymer and uses thereof |
US10071141B2 (en) | 2015-05-08 | 2018-09-11 | Spectral Platforms, Inc. | Albumin-based non-covalent complexes and methods of use thereof |
US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
US9572783B1 (en) * | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
CN105646869B (zh) * | 2016-01-04 | 2018-01-16 | 中国海洋大学 | 一种水溶性虾青素衍生物及其制备方法 |
US11185523B2 (en) | 2016-03-24 | 2021-11-30 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
CN106748946A (zh) * | 2017-02-14 | 2017-05-31 | 烟台固特丽生物科技股份有限公司 | 一种含水溶性虾青素作物营养液的制备方法 |
US11105747B2 (en) | 2017-03-20 | 2021-08-31 | Spectral Platforms, Inc. | Spectroscopic methods to detect and characterize microorganisms |
US20210283055A1 (en) * | 2018-05-03 | 2021-09-16 | L.E.A.F. Holdings Group Llc | Carotenoid compositions and uses thereof |
JP2021176821A (ja) * | 2018-08-01 | 2021-11-11 | アスタファーマシューティカルズ株式会社 | 新規カロテノイド関連誘導体、その塩又はエステル類若しくはアミド類 |
CN109678771A (zh) * | 2018-12-28 | 2019-04-26 | 广州立达尔生物科技股份有限公司 | 一种叶黄素甘氨酸酯及其盐酸盐的制备方法 |
JP2022549503A (ja) * | 2019-09-27 | 2022-11-25 | カーダックス、インコーポレイティッド | アスタキサンチンエステルおよびその使用方法 |
FR3105790B1 (fr) * | 2019-12-26 | 2022-01-14 | Biophytis | Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires |
CN111257466B (zh) * | 2020-02-27 | 2022-04-01 | 南宁海关技术中心 | 一种红心鸭蛋中类胡萝卜素含量的测定方法 |
CN113788867B (zh) * | 2021-06-30 | 2023-12-26 | 东北林业大学 | 一种叶黄素水溶性衍生物及其制备工艺 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH314001A (de) * | 1952-12-18 | 1956-05-31 | Hoffmann La Roche | Verfahren zur Herstellung von Vitamin-A-Estern |
CH420822A (de) * | 1960-10-17 | 1966-09-15 | Hoffmann La Roche | Wasserdispergierbare Carotinoidzubereitung |
US3354218A (en) * | 1963-05-10 | 1967-11-21 | Hoffmann La Roche | Process for preparing 4-(2, 6, 6-trimethyl-4-methoxy-1-cyclohexen-1-yl)-3-buten-2-one |
FR2076448A5 (pt) * | 1970-01-15 | 1971-10-15 | Rhone Poulenc Sa | |
US3788468A (en) * | 1973-05-01 | 1974-01-29 | Univ Virginia | Process for increasing oxygen diffusivity |
US3853993A (en) * | 1973-05-01 | 1974-12-10 | Univ Virginia | Process for increasing oxygen diffusivity and method for treating atherosclerosis |
US3989757A (en) * | 1973-08-29 | 1976-11-02 | Hoffmann-La Roche Inc. | Isomerizing cis-carotenoids to all-trans-carotenoids |
CH609320A5 (pt) * | 1974-06-20 | 1979-02-28 | Hoffmann La Roche | |
US3965261A (en) * | 1975-04-29 | 1976-06-22 | University Of Virginia | Method for treating papillomas |
US3975519A (en) * | 1975-06-09 | 1976-08-17 | University Of Virginia | Method for increasing the oxygen partial pressure in the bloodstream of mammals |
US4070460A (en) * | 1975-11-10 | 1978-01-24 | University Of Virginia Patents Foundation | Method for treating cerebral edema |
US4009270A (en) * | 1975-11-21 | 1977-02-22 | The University Of Virginia | Method for treating spinal cord injury |
CH623304A5 (pt) * | 1975-11-30 | 1981-05-29 | Hoffmann La Roche | |
US4038144A (en) * | 1976-04-19 | 1977-07-26 | The University Of Virginia | Method of increasing fermentation yields |
US4046880A (en) * | 1976-04-20 | 1977-09-06 | The University Of Virginia | Method of treating hypertension |
JPS6053031B2 (ja) * | 1978-03-31 | 1985-11-22 | 武田薬品工業株式会社 | スピロ化合物およびその製造方法 |
US4176179A (en) * | 1978-04-17 | 1979-11-27 | The University Of Virginia Alumni Patents Foundation | Method for treating arthritis |
DE2965093D1 (en) * | 1978-06-02 | 1983-05-05 | Hoffmann La Roche | Derivatives of cyclohexene, process for their peparation, as well as their uses |
DE2964401D1 (en) * | 1978-06-02 | 1983-02-03 | Hoffmann La Roche | Process for the preparation of cyclohexenyl derivatives, and intermediates produced in the synthesis |
DE3048000A1 (de) * | 1980-12-19 | 1982-07-15 | Basf Ag | Stabile injizierbare (beta)-carotin-solubilisate und verfahren zu ihrer herstellung |
DE3273463D1 (en) * | 1981-10-16 | 1986-10-30 | Hoffmann La Roche | Process for the preparation of cyclohexene derivatives, and a starting product and intermediary products in this process |
EP0085763B1 (de) * | 1982-02-09 | 1985-06-05 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung von Cyclohexenderivaten |
EP0101597B1 (de) * | 1982-08-20 | 1988-06-22 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung von Astaxanthin und Zwischenprodukten in der Astaxanthin-Synthese |
US4491574A (en) * | 1983-03-02 | 1985-01-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Reduction of high dose aspirin toxicity by dietary vitamin A |
DE3582439D1 (de) * | 1984-01-28 | 1991-05-16 | Roshdy Ismail | Mittel zur behandlung von herzerkrankungen. |
US5346488A (en) * | 1985-04-08 | 1994-09-13 | The General Hospital Corporation | Laser-induced ablation of atherosclerotic plaque |
US4851339A (en) * | 1986-04-01 | 1989-07-25 | Hills Christopher B | Extraction of anti-mutagenic pigments from algae and vegetables |
DK171297B1 (da) * | 1987-03-27 | 1996-08-26 | Hoffmann La Roche | Fremgangsmåde til fremstilling af cyclohexenderivater som mellemprodukter til fremstilling af zeaxanthin samt cyclohexenderivater |
US5057494A (en) * | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
DE59003205D1 (de) * | 1989-07-25 | 1993-12-02 | Hoffmann La Roche | Verfahren zur Herstellung von Carotinoidpräparaten. |
US5278189A (en) * | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
AU660630B2 (en) * | 1990-10-01 | 1995-07-06 | Brigham And Women's Hospital | Beta-carotene and vitamin E therapy for inhibition of major vascular events |
US6132790A (en) * | 1991-09-06 | 2000-10-17 | Betatene Limited | Carotenoid composition |
EP0746202A4 (en) * | 1992-01-06 | 1997-06-25 | Health Maintenance Programs | COMPOSITION CONTAINING A PHARMACEUTICALLY ACTIVE ANTI-OXIDANT AND METHOD FOR USE IN THE PREVENTION AND TREATMENT OF RESTENOSIS AFTER ANGIOPLASTY |
US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
US5328845A (en) * | 1992-03-27 | 1994-07-12 | Universal Foods Corporation | Fungal negative microorganism capable of producing high levels of beta-carotene |
IL104736A0 (en) * | 1992-03-27 | 1993-06-10 | Zeagen Inc | Method for producing beta-carotene using a fungal mated culture |
EP0565989B1 (de) * | 1992-04-14 | 1997-06-25 | F. Hoffmann-La Roche Ag | Präparate von fettlöslichen Substanzen |
US5310764A (en) * | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
EP0643692B1 (en) * | 1992-06-04 | 1999-11-24 | Betatene Pty. Ltd. | High cis beta-carotene composition |
GB9219524D0 (en) * | 1992-09-15 | 1992-10-28 | Smithkline Beecham Plc | Novel composition |
US5310554A (en) * | 1992-10-27 | 1994-05-10 | Natural Carotene Corporation | High purity beta-carotene |
DE19609538A1 (de) * | 1996-03-11 | 1997-09-18 | Basf Ag | Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung |
ES2178651T3 (es) * | 1993-03-22 | 2003-01-01 | Cognis Australia Pty Ltd | Compuestos carotenoides terapeuticos deispersables en agua. |
ES2149264T3 (es) * | 1993-03-22 | 2000-11-01 | Cognis Australia Pty Ltd | Agente terapeutico para el tratamiento de melanomas. |
DE69424719T2 (de) * | 1993-06-24 | 2000-11-02 | Hoffmann La Roche | Pigmentierung mit Carotinoiden |
US6218436B1 (en) * | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
DE4322277A1 (de) * | 1993-07-05 | 1995-01-12 | Basf Ag | Verbessertes Verfahren zur Herstellung von Astaxanthin, neue Zwischenprodukte hierfür sowie ein Verfahren zu deren Herstellung |
FR2707184B1 (fr) * | 1993-07-08 | 1995-08-11 | Rhone Poulenc Nutrition Animal | Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique. |
US5607839A (en) * | 1993-07-22 | 1997-03-04 | Nippon Oil Company, Ltd. | Bacteria belonging to new genus process for production of carotenoids using same |
JP3249867B2 (ja) * | 1993-10-21 | 2002-01-21 | 株式会社クラレ | アスタキサンチンの製造方法 |
CH685189A5 (de) * | 1993-11-19 | 1995-04-28 | Marigen Sa | Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamen Xanthophyll-Estern. |
US6428816B1 (en) * | 1994-04-08 | 2002-08-06 | Cognis Australia Pty., Ltd. | Carotenoid agent for inhibiting the conversion of epithelial cells to tumors |
SE9401738D0 (sv) * | 1994-05-19 | 1994-05-19 | Ewos Ab | Bioactive feed |
JPH0873312A (ja) * | 1994-09-02 | 1996-03-19 | Noevir Co Ltd | 皮膚外用剤 |
SE503336C2 (sv) * | 1994-09-19 | 1996-05-28 | Asta Carotene Ab | Medel och sätt för att öka produktionen av/hos fjäderfän |
US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
EP0718284B1 (en) * | 1994-12-21 | 1999-08-18 | F. Hoffmann-La Roche Ag | Carotenoid ketones and esters |
US5643943A (en) * | 1994-12-23 | 1997-07-01 | Alcon Laboratories, Inc. | Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis |
US5589468A (en) * | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
US5886053A (en) * | 1995-02-03 | 1999-03-23 | Basf Aktiengesellschaft | Use of carotenoids for producing drugs for the treatment of dermatoses |
US5532009A (en) * | 1995-06-07 | 1996-07-02 | The Procter & Gamble Company | Fat substitutes containing water soluble beta-carotene |
JPH08337592A (ja) * | 1995-06-13 | 1996-12-24 | Kaiyo Bio Technol Kenkyusho:Kk | 新規カロテノイド |
JPH0984591A (ja) * | 1995-09-26 | 1997-03-31 | Kaiyo Bio Technol Kenkyusho:Kk | カロテノイド硫酸エステルおよびその製造方法 |
US6060511A (en) * | 1995-10-05 | 2000-05-09 | Gainer; John L. | Trans-sodium crocetinate, methods of making and methods of use thereof |
EP0798305B1 (en) * | 1995-10-17 | 2007-10-03 | Showa Denko Kabushiki Kaisha | High-purity tocopherol phosphates, process for the preparation thereof, method for analysis thereof, and cosmetics |
JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
US5854015A (en) * | 1995-10-31 | 1998-12-29 | Applied Food Biotechnology, Inc. | Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion |
US5827539A (en) * | 1995-12-28 | 1998-10-27 | Amway Corporation | Dry carotenoid-oil powder and process for making same |
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
US6232060B1 (en) * | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
JPH09202730A (ja) * | 1996-01-24 | 1997-08-05 | Nippon Mektron Ltd | 発ガン抑制作用剤 |
US5801159A (en) * | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
DE19609477A1 (de) * | 1996-03-11 | 1997-09-18 | Basf Ag | Stabile wäßrige Solubilisate von Carotinoiden und Vitamine |
DE19609476A1 (de) * | 1996-03-11 | 1997-09-18 | Basf Ag | Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen |
SE506191C2 (sv) * | 1996-03-27 | 1997-11-17 | Astacarotene Ab | Medel och sätt för att öka produktionen av/hos däggdjur |
DK0807431T3 (da) * | 1996-05-14 | 2004-07-26 | Dsm Ip Assets Bv | Fremgangsmåde til fremstilling af carotenoidpræparater |
DE19637517A1 (de) * | 1996-09-13 | 1998-03-19 | Basf Ag | Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen |
DE19649062A1 (de) * | 1996-11-27 | 1998-05-28 | Basf Ag | Flüssige, mit Öl mischbare Carotinoid-Zubereitungen |
AU7888498A (en) * | 1996-12-25 | 1998-07-31 | Designer Foods Association Ltd. | Carcinogenesis inhibitors |
PT1003501E (pt) * | 1997-04-02 | 2005-07-29 | Brigham & Womens Hospital | Utilizacao de um agente para reduzir o risco de doencas cardiovasculares |
US5858700A (en) * | 1997-04-03 | 1999-01-12 | Kemin Foods, Lc | Process for the isolation and purification of lycopene crystals |
AU752468B2 (en) * | 1997-04-04 | 2002-09-19 | Phyllis E. Bowen | Lutein esters having high bioavailability |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US5876782A (en) * | 1997-05-14 | 1999-03-02 | Kemin Industries, Inc. | Method for the conversion of xanthophylls in plant material |
JPH10327865A (ja) * | 1997-05-29 | 1998-12-15 | Kirin Brewery Co Ltd | カロテノイド配糖体およびその製造法 |
SE512531C2 (sv) * | 1997-09-04 | 2000-03-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur |
US6008417A (en) | 1997-10-20 | 1999-12-28 | Roche Vitamins Inc. | Process for making metabolites of lycopene |
US5959138A (en) * | 1997-11-25 | 1999-09-28 | Industrial Organica S.A. De C.V. | Short chain diesters and process for making the same |
SE511237C2 (sv) * | 1997-12-16 | 1999-08-30 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor |
DE19802134A1 (de) * | 1998-01-21 | 1999-07-22 | Basf Ag | Verwendung von Carotinoid-Aggregaten als Färbemittel |
US6020003A (en) * | 1998-02-23 | 2000-02-01 | Basf Corporation | Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin |
US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
NL1010351C2 (nl) * | 1998-10-19 | 2001-01-08 | Werklust & Beheer B V | Esters van caroteno´den voor gebruik in de preventie en behandeling van oogaandoeningen. |
US6075058A (en) * | 1998-12-12 | 2000-06-13 | Tufts University | Compositions for increased bioavailability of carotenoids |
US6399105B1 (en) * | 1999-01-20 | 2002-06-04 | Peter Donald Collin | Sea cucumber carotenoid lipid fraction products and methods of use |
JP4491090B2 (ja) * | 1999-10-08 | 2010-06-30 | ヒガシマル醤油株式会社 | アポトーシス誘導剤 |
US6426362B1 (en) * | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
US20020051998A1 (en) | 1999-12-08 | 2002-05-02 | California Institute Of Technology | Directed evolution of biosynthetic and biodegradation pathways |
US6344214B1 (en) * | 1999-12-13 | 2002-02-05 | Cyanotech Corporation | Method for retarding and ameliorating fever blisters and canker sores |
US6258855B1 (en) * | 2000-02-08 | 2001-07-10 | Cyanotech Corporation | Method of retarding and ameliorating carpal tunnel syndrome |
AU5137901A (en) * | 2000-04-06 | 2001-10-23 | Coastside Res | Method to inhibit lipoxygenase and cancer cell proliferation |
US20030104090A1 (en) | 2000-05-05 | 2003-06-05 | Levy Pedro E. | Supplements containing annatto extracts and carotenoids and methods for using the same |
US6579544B1 (en) * | 2000-05-31 | 2003-06-17 | Nutriex, L.L.C. | Method for supplementing the diet |
US20020110604A1 (en) * | 2000-08-11 | 2002-08-15 | Ashni Naturaceuticals, Inc. | Composition exhibiting synergistic antioxidant activity |
JP2004515508A (ja) | 2000-12-16 | 2004-05-27 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 化合物の健康促進組成物 |
CA2438876C (en) * | 2001-02-23 | 2010-09-14 | Barlovento International | Novel carotenoid esters |
US6984523B2 (en) | 2001-08-02 | 2006-01-10 | E.I. Du Pont De Nemours And Company | Carotenoid ketolase gene |
GB0119052D0 (en) * | 2001-08-03 | 2001-09-26 | Mars Uk Ltd | Foodstuff |
AU2003205699B8 (en) * | 2002-02-06 | 2008-06-05 | Dsm Ip Assets B.V. | Astaxanthin esters |
US7514107B2 (en) * | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
US20050228188A1 (en) * | 2002-04-30 | 2005-10-13 | Suntory Limited | Astaxanthin medium-chain fatty acid ester, process for producing the same and composition containing the ester |
US20050004235A1 (en) | 2002-07-29 | 2005-01-06 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
US20050059635A1 (en) | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels |
US20050059659A1 (en) | 2002-07-29 | 2005-03-17 | Lockwood Samuel Fournier | Carotenoid analogs or derivatives for controlling C-reactive protein levels |
US20050148517A1 (en) * | 2002-07-29 | 2005-07-07 | Lockwood Samuel F. | Carotenoid ether analogs or derivatives for controlling connexin 43 expression |
US20050049248A1 (en) | 2002-07-29 | 2005-03-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels |
US7320997B2 (en) | 2002-07-29 | 2008-01-22 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease |
US7521584B2 (en) | 2002-07-29 | 2009-04-21 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of disease |
US7723327B2 (en) | 2002-07-29 | 2010-05-25 | Cardax Pharmaceuticals, Inc. | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease |
US20050143475A1 (en) | 2002-07-29 | 2005-06-30 | Lockwood Samuel F. | Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury |
EP2392562B1 (en) * | 2002-07-29 | 2018-03-07 | Cardax Pharma, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
US20050009788A1 (en) | 2002-07-29 | 2005-01-13 | Lockwood Samuel Fournier | Carotenoid ester analogs or derivatives for controlling connexin 43 expression |
US7763649B2 (en) | 2002-07-29 | 2010-07-27 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs or derivatives for controlling connexin 43 expression |
US7375133B2 (en) | 2002-07-29 | 2008-05-20 | Cardax Pharmaceuticals, Inc. | Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20050026874A1 (en) | 2002-07-29 | 2005-02-03 | Lockwood Samuel Fournier | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease |
US7345091B2 (en) | 2002-07-29 | 2008-03-18 | Cardax Pharmaceuticals, Inc. | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
US20060058269A1 (en) * | 2004-04-14 | 2006-03-16 | Lockwood Samuel F | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
WO2005102356A1 (en) * | 2004-04-14 | 2005-11-03 | Hawaii Biotech, Inc. | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
US20060111580A1 (en) * | 2004-10-01 | 2006-05-25 | Lockwood Samuel F | Methods for the synthesis of chiral dihydroxy ketone intermediates useful for the chiral synthesis of carotenoids |
-
2003
- 2003-07-29 EP EP10185924.7A patent/EP2392562B1/en not_active Expired - Lifetime
- 2003-07-29 KR KR1020057001714A patent/KR20050069975A/ko not_active Application Discontinuation
- 2003-07-29 BR BRPI0313155A patent/BRPI0313155B8/pt not_active IP Right Cessation
- 2003-07-29 AU AU2003256982A patent/AU2003256982A1/en not_active Abandoned
- 2003-07-29 WO PCT/US2003/023706 patent/WO2004011423A2/en active Search and Examination
- 2003-07-29 JP JP2005505633A patent/JP4601549B2/ja not_active Expired - Fee Related
- 2003-07-29 CN CN2010101657116A patent/CN101845009B/zh not_active Expired - Fee Related
- 2003-07-29 EP EP03772051.3A patent/EP1532108B1/en not_active Expired - Lifetime
- 2003-07-29 US US10/629,538 patent/US7145025B2/en not_active Expired - Lifetime
- 2003-07-29 CA CA2495167A patent/CA2495167C/en not_active Expired - Fee Related
- 2003-07-29 MX MXPA05001202A patent/MXPA05001202A/es not_active Application Discontinuation
- 2003-07-29 CN CN03823260XA patent/CN1708480B/zh not_active Expired - Fee Related
-
2004
- 2004-03-04 US US10/793,703 patent/US7317008B2/en not_active Expired - Lifetime
- 2004-03-04 US US10/793,702 patent/US20050075337A1/en not_active Abandoned
- 2004-03-04 US US10/793,696 patent/US20050065097A1/en not_active Abandoned
-
2005
- 2005-02-03 NO NO20050619A patent/NO20050619L/no not_active Application Discontinuation
-
2006
- 2006-02-17 US US11/357,897 patent/US7592449B2/en not_active Expired - Lifetime
- 2006-04-20 HK HK06104731.0A patent/HK1084380A1/xx not_active IP Right Cessation
-
2010
- 2010-07-29 JP JP2010170929A patent/JP5187700B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-28 HK HK11103076.8A patent/HK1148997A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2003256982A1 (en) | 2004-02-16 |
CA2495167A1 (en) | 2004-02-05 |
HK1084380A1 (en) | 2006-07-28 |
US20060229446A1 (en) | 2006-10-12 |
HK1148997A1 (en) | 2011-09-23 |
WO2004011423A2 (en) | 2004-02-05 |
CN1708480A (zh) | 2005-12-14 |
EP2392562A1 (en) | 2011-12-07 |
JP2010248243A (ja) | 2010-11-04 |
KR20050069975A (ko) | 2005-07-05 |
NO20050619L (no) | 2005-04-27 |
CN1708480B (zh) | 2010-12-15 |
JP2006517197A (ja) | 2006-07-20 |
EP2392562B1 (en) | 2018-03-07 |
CA2495167C (en) | 2018-08-21 |
US7145025B2 (en) | 2006-12-05 |
US20040162329A1 (en) | 2004-08-19 |
CN101845009B (zh) | 2012-10-03 |
MXPA05001202A (es) | 2005-11-23 |
US20050065097A1 (en) | 2005-03-24 |
JP4601549B2 (ja) | 2010-12-22 |
US20050037995A1 (en) | 2005-02-17 |
US7317008B2 (en) | 2008-01-08 |
US20050075337A1 (en) | 2005-04-07 |
CN101845009A (zh) | 2010-09-29 |
EP1532108A2 (en) | 2005-05-25 |
EP1532108B1 (en) | 2016-06-29 |
JP5187700B2 (ja) | 2013-04-24 |
US7592449B2 (en) | 2009-09-22 |
BR0313155A (pt) | 2005-07-12 |
BRPI0313155B1 (pt) | 2018-11-06 |
WO2004011423A3 (en) | 2004-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0313155B8 (pt) | composto químico derivado ou análogo de carotenóide, composição farmacêutica, e, uso do composto | |
ES2189784T3 (es) | Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos. | |
BR0317891A (pt) | Tratamento de ferimentos de pele usando polienilfosfatidil colina e alcanolaminas | |
BR9909393A (pt) | Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor | |
JO3147B1 (ar) | مشتقات 2،3 - داي هيدرو إميدازو}1،2-{c كينازولين بها استبدال مفيدة لعلاج اضطرابات فرط التكاثر الخلوي والامراض المتعلق بتولد الاوعية | |
CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
DE69328771T2 (de) | Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge | |
SI1819227T1 (sl) | Farmacevtska formulacija decitabina | |
AUPR177300A0 (en) | Therapeutic methods | |
WO2006063111A3 (en) | Pharmaceutical formulations cytidine analogs and derivatives | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
BRPI0608654B8 (pt) | uso de 5-amino-1-b-d-(5-benzilamino-5-desóxi-1-b-d-ribofuranosil)imidazol-4-carboxamida, 5-amino-1-(5-amino-5-desóxi-b-d-ribofuranosil)imidazol-4-n-[(4-clorofenil)metil]carboxamida ou um sal dos mesmos | |
BR0313630A (pt) | Composição para aplicação tópica, sistema para o tratamento de caspa, métodos para o tratamento e/ou prevenção da caspa e da coceira do couro cabeludo e usos de uma combinação sinérgica | |
MX2023001997A (es) | Compuestos biciclicos, composiciones y usos de los mismos. | |
BR0009847A (pt) | Kit de partes, método de preparação de um kit de partes, formulação farmacêutica, método de tratamento de uma condição na qual inibição de trombina é requerida ou desejada, e, uso de um inibidor de trombina, ou de um derivado farmaceuticamente aceitável do mesmo | |
IT1272994B (it) | Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario.- | |
BRPI0512012A (pt) | composto ou um derivado farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritmia, e, processo para a preparação de um composto | |
BR0015770A (pt) | Compostos bicìclicos análogos de vitamina d, uso de um composto, composição farmacêutica, composição cosmética e uso de uma composição cosmética | |
BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
BR0208463A (pt) | Compostos farmaceuticamente ativos | |
BR9910628A (pt) | Uso de um composto da série da benzofuroxana, composição farmacêutica, e, processos para a preparação de uma formulação parenteral e para o tratamento de um mamìfero, incluindo um ser humano, de doenças cardìacas da coronária | |
HK1090062A1 (en) | Colchicoside analogues | |
BR0113175A (pt) | Derivados da quinolina como agentes antiinflamação | |
CY1106961T1 (el) | Χρηση παραγοντα μειωσης περιεκτικοτητας ομοκυστεϊνης πλασματος για τη μειωση του κινδυνου θρομβοεμβολικης παρενεργειας που προκαλειται απο ορμονες τυπου προγεστερονης | |
ES2093226T3 (es) | Retinoides sustituidos con un ciclo ditiano y su empleo, procedimiento de preparacion de dichos compuestos, composiciones cosmetica y farmaceutica que los contienen y empleo terapeutico de esta ultima. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: CARDAX PHARMACEUTICALS, INC. (US) Free format text: TRANSFERIDO DE: HAWAII BIOTECH, INC. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2630 DE 01-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |